Mark James Litton - Dec 31, 2024 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Signature
/s/ Mark Worthington, Attorney-in-Fact for Mark James Litton
Stock symbol
ATHA
Transactions as of
Dec 31, 2024
Transactions value $
-$14,108
Form type
4
Date filed
1/3/2025, 05:04 PM
Previous filing
Oct 3, 2024

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Restricted Stock Units Options Exercise $0 -108K -33.33% $0.00 217K Dec 31, 2024 Common Stock 108K Direct F6, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person.
F2 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $0.5414 to $0.5939, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 Reflects Common Stock held by Irrevocable Trust of OSL held for the benefit of Dr. Litton's children.
F4 Reflects Common Stock held by Irrevocable Trust of SWL held for the benefit of Dr. Litton's children.
F5 Reflects Common Stock held by Irrevocable Trust of WGL held for the benefit of Dr. Litton's children.
F6 RSUs convert into common stock on a one-for-one basis.
F7 Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.
F8 On October 3, 2024, the reporting person was granted 325,000 RSUs. One-third (1/3rd) of the RSUs vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the reporting person continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan (the "Plan")) through the applicable vesting dates.